First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors

Background Inducible costimulator (ICOS) receptor belongs to the CD28/CTLA immunoglobulin super family, whose expression is restricted to T cells and is weakly expressed on resting TH17, follicular helper T cells, and regulatory T cells, but is highly induced on CD4+ and CD8+ T cells on activation b...

Full description

Saved in:
Bibliographic Details
Main Authors: David Turner, Antoine Italiano, Victor Moreno, Steven Hirschfeld, Juan Martin-Liberal, Michele Maio, Todd M Bauer, Christophe Le Tourneau, Danny Rischin, Catherine Ellis, Eric Angevin, Aaron Hansen, Helen Zhou, Ivan Diaz-Padilla, Frans Opdam, Sapna Yadavilli, Marc Ballas
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e011475.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/8/e011475.full

Similar Items